DLL3 is an emerging therapeutic target in small cell lung cancer and other neuroendocrine carcinomas, with 1 FDA-approved therapy and several others under investigation.
Aubrey R. Lasko, PharmD, BCOP
Advertisement
Articles by Aubrey R. Lasko, PharmD, BCOP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Emerging Biomarkers Open New Frontiers in Lung Cancer Therapy
2
Targeted α-Particle Radioligand Therapy Shows Promising Activity, Low Toxicity in SSTR2-Positive Neuroendocrine Tumors
3
Dato-DXd Doubles Response Rates and Extends Survival in First-Line Metastatic TNBC
4
Transforming HER2+ Metastatic Breast Cancer Treatment With Targeted ADC Therapy
5
